3.2 USD
-0.06 (-1.84%)
3.08 USD
-0.12 (-3.75%)
We assign a fundamental rating of 2 out of 10 to SNOA. SNOA was compared to 192 industry peers in the Pharmaceuticals industry. While SNOA seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SNOA is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year SNOA has reported negative net income.
SNOA had a negative operating cash flow in the past year.
In the past 5 years SNOA always reported negative net income.
In the past 5 years SNOA always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -25.11%, SNOA perfoms like the industry average, outperforming 54.69% of the companies in the same industry.
SNOA's Return On Equity of -91.87% is in line compared to the rest of the industry. SNOA outperforms 41.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.11% | ||
| ROE | -91.87% | ||
| ROIC | N/A |
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNOA has a Gross Margin of 37.68%. This is comparable to the rest of the industry: SNOA outperforms 59.38% of its industry peers.
In the last couple of years the Gross Margin of SNOA has declined.
SNOA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
SNOA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SNOA has more shares outstanding
Compared to 5 years ago, SNOA has less shares outstanding
Compared to 1 year ago, SNOA has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -18.66, we must say that SNOA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -18.66, SNOA is doing worse than 84.38% of the companies in the same industry.
SNOA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
SNOA's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. SNOA outperforms 57.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -18.66 |
ROIC/WACCN/A
WACC8.8%
2.3 Liquidity
A Current Ratio of 2.89 indicates that SNOA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.89, SNOA is in line with its industry, outperforming 51.56% of the companies in the same industry.
A Quick Ratio of 2.05 indicates that SNOA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.05, SNOA perfoms like the industry average, outperforming 43.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.05 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 55.30% over the past year.
SNOA shows a strong growth in Revenue. In the last year, the Revenue has grown by 25.02%.
SNOA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.44% yearly.
EPS 1Y (TTM)55.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.76%
Revenue 1Y (TTM)25.02%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%56.58%
3.2 Future
SNOA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.06% yearly.
SNOA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 17.80% yearly.
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
SNOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as SNOA's earnings are expected to grow with 15.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.06%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for SNOA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.2
-0.06 (-1.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.31%
Inst Owner Change-38.77%
Ins Owners1.28%
Ins Owner Change0%
Market Cap5.28M
Revenue(TTM)16.94M
Net Income(TTM)-3.48M
Analysts85.71
Price Target15.1 (371.87%)
Short Float %2.09%
Short Ratio0.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-23.22%
Min EPS beat(2)-45.24%
Max EPS beat(2)-1.2%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)13.07%
Min Revenue beat(2)-2.81%
Max Revenue beat(2)28.95%
Revenue beat(4)1
Avg Revenue beat(4)-1.23%
Min Revenue beat(4)-17.11%
Max Revenue beat(4)28.95%
Revenue beat(8)1
Avg Revenue beat(8)-8.23%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.31 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.39 | ||
| P/tB | 1.39 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.2
EYN/A
EPS(NY)-0.46
Fwd EYN/A
FCF(TTM)-1.42
FCFYN/A
OCF(TTM)-1.32
OCFYN/A
SpS10.26
BVpS2.3
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -25.11% | ||
| ROE | -91.87% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 37.68% | ||
| FCFM | N/A |
ROA(3y)-29.93%
ROA(5y)-28.63%
ROE(3y)-73.9%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.69%
GM growth 5Y-3.32%
F-Score4
Asset Turnover1.22
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 121.32% | ||
| Cap/Sales | 0.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.05 | ||
| Altman-Z | -18.66 |
F-Score4
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)91.77%
Cap/Depr(5y)85.45%
Cap/Sales(3y)0.91%
Cap/Sales(5y)0.96%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.76%
EPS Next Y-96.42%
EPS Next 2Y15.06%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)25.02%
Revenue growth 3Y4.2%
Revenue growth 5Y-4.44%
Sales Q2Q%56.58%
Revenue Next Year11.38%
Revenue Next 2Y17.8%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.85%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y48.58%
OCF growth 3YN/A
OCF growth 5YN/A
SONOMA PHARMACEUTICALS INC / SNOA FAQ
What is the ChartMill fundamental rating of SONOMA PHARMACEUTICALS INC (SNOA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to SNOA.
What is the valuation status for SNOA stock?
ChartMill assigns a valuation rating of 0 / 10 to SONOMA PHARMACEUTICALS INC (SNOA). This can be considered as Overvalued.
Can you provide the profitability details for SONOMA PHARMACEUTICALS INC?
SONOMA PHARMACEUTICALS INC (SNOA) has a profitability rating of 1 / 10.